NEWS RELEASE

Teijin Receives Marketing Approval for Merz’s Xeomin®
Botulinum Toxin Type A in JapanTokyo, Japan, June 29, 2020 --- Teijin Pharma Limited, the core company of the TeijinGroup’s healthcare business, and Merz Pharma GmbH & Co. KGaA, a leading aesthetics
and neurotoxin company, jointly announced today that Teijin Pharma has been granted
approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin®
(incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatmentof upper limb spasticity.
Xeomin® is effective in treating peripheral cholinergic nerve endings by weakening thecontraction of voluntary muscles, and it relieves muscle tone by inhibiting the releaseof a neurotransmitter called acetylcholine. The highly purified neurotoxin, the only
active ingredient in Xeomin®, is made by removing complexing proteins from botulinum
toxin type A, which is produced by Clostridium botulinum, using purification technology
developed by Merz Pharma GmbH & Co. KGaA. The lack of complexing proteinsenables Xeomin® to reduce the production of neutralizing antibodies capable oflowering efficacy.
Xeomin® is being distributed by Merz Pharmaceuticals GmbH in more than 70
countries to treat patients with upper limb spasticity, cervical dystonia, blepharospasm
and upper facial wrinkles, or hypersalivation. Teijin Pharma signed an exclusive licenseand co-development agreement for Xeomin® in Japan with Merz Pharma GmbH & Co.
KGaA in 2017. In August 2019, Teijin Pharma applied for marketing approval basedon a significant improvement in the modified ashworth scale (MAS) score of the wrist
flexion, which was observed in a phase-III clinical trial conducted by Merz in Japan.
Upper limb spasticity is a symptom of upper motor neuron syndrome, which is expressed
mainly by increased muscle tone of upper limbs and the hyperexcitability of the stretch
reflex as a sequela of stroke. The main symptoms are motor paralysis, hyperflexion,
appearance of pathological reflexes, and sensory disturbances that complicate or
impede activities in daily living.
Conventional treatment of upper limb spasticity includes physical rehabilitation and theuse of oral muscle relaxants or neuromuscular blockers such as botulinum toxin type A.
Injections of botulinum toxin type A are a Grade A recommendation in the Japanese
Guidelines for the Management of Stroke 2015.
Teijin Pharma already provides various pharmaceuticals and medical devices that help
to contribute to improving quality of life of patients suffering from musculoskeletal

diseases,” said Ichiro Watanabe, president of Teijin Pharma Limited. “We, responding todemographic change and increased health consciousness, are launching effective newdrugs and providing other solutions to realize more sustainable societies. Teijin Pharma
continues to contribute to improving the quality of life (QOL) of patients by providing newtreatment options for diseases with high unmet needs.”"At Merz Therapeutics, we do everything to bring better outcomes to more patients.
Therefore, we are very proud of our partnership with Teijin to make Xeomin® available tophysicians and patients in Japan,” said Stefan Brinkmann, CEO Merz Therapeutics. “Weare confident that this treatment option can help patients with upper limb spasticity inJapan to experience more good days and achieve their unique goals.”
About Xeomin®
Brand nameNonproprietaryname
Dosage formIndicationDosage andadministration

Xeomin® 50 units for intramuscular injection
Xeomin®100 units for intramuscular injection
Xeomin® 200 units for intramuscular injection

incobotulinumtoxinA
Injection (vial)
Upper limb spasticity
In general, for adults, Xeomin® should be injected into multiple tonic
muscles.* The maximum dose per administration is 400 units,
however, the dose should be appropriately reduced to the minimum
depending on the type and number of targeted tonic muscles.
Repeated doses are permissible if the effect of a previous dose
diminish. The dosing interval should be 12 weeks or longer, but
may be shortened to 10 weeks depending on the symptoms.
*Tonic muscles: flexor carpi radialis, flexor carpi ulnaris, flexor
digitorum dorsi, flexor digitorum brevis, radial biceps, biceps brachii,brachial musculature, pronation of the pronator, flexor progenitor,flexor pollicis longus, adductor pollicis longus, flexor pollicis
brevis/opposite thumb muscle, etc.

Xeomin® is the registered trademark of Merz Pharma GmbH & Co. KGaA.

About the Teijin GroupTeijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare

equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions,” Teijin aims to be a company that
supports the society of the future. The group comprises more than 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 853.7 billion (USD 8.0 billion) and total assets of JPY 1,004.2 billion (USD9.4 billion) in the fiscal year that ended on March 31, 2020.
About Merz Therapeutics
Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is dedicated toimproving the lives of patients around the world. With its relentless research,development, and culture of innovation, Merz Therapeutics strives to serve unmet patientneeds and realize better outcomes. Merz Therapeutics seeks to address the uniqueneeds of people who suffer from movement disorders, neurological conditions, liverdisease, and other health conditions that severely impact patients’ quality of life. Merz
Therapeutics is headquartered in Frankfurt, Germany and is represented in more than
90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz
Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned
company that has dedicated more than 110 years to developing innovations that meetpatient and customer needs.
Please visit www.merz.com
Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp